MaxCyte, Inc. filings document the regulatory record for a Delaware life sciences tools company with Nasdaq-listed common stock. Its Form 8-K disclosures cover operating results and financial condition, corporate presentations, executive appointments, compensatory arrangements, listing-compliance notices, and cost-structure actions tied to workforce and operating changes.
MaxCyte proxy materials cover annual stockholder meeting matters, including director elections, board-class structure and auditor ratification. Together, the filings describe governance, capital-market status, material events, and formal disclosures related to MaxCyte’s cell-engineering platform business, Strategic Platform License model, and public-company reporting obligations.
MaxCyte reported weaker 2025 results and trimmed its outlook for 2026. Full year 2025 revenue was $33.0 million, down from $38.6 million, with total core revenue falling to $29.6 million. The company posted a 2025 net loss of $44.6 million and an EBITDA loss of $47.6 million, including restructuring and goodwill impairment charges.
Fourth quarter 2025 revenue was $7.3 million, a 16% decline year over year, while core revenue dropped 22%. Despite this, gross margin stayed high at 81% for 2025. Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025, and MaxCyte expects to end 2026 with at least $136 million. For 2026, it guides to total revenue of $30–32 million, including core revenue of $25–27 million and $5 million from Strategic Platform License (SPL) programs, reflecting continued customer headwinds.
MaxCyte, Inc. reported that Nasdaq notified the company its common stock no longer meets the Nasdaq Global Select Market’s minimum bid price requirement because the closing bid has been below $1.00 per share for 30 consecutive trading days. The stock remains listed for now and continues to trade on Nasdaq.
MaxCyte has 180 calendar days, until September 14, 2026, to regain compliance by having a closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading days. If it fails to do so, the company may seek an additional 180-day period by transferring to the Nasdaq Capital Market, subject to meeting other listing standards. Nasdaq could ultimately move to delist the shares, and there is no assurance MaxCyte will regain or maintain compliance.
MAXCYTE, INC. Chief Financial Officer Douglas J. Swirsky reported an open-market sale of 10,142 shares of common stock at a weighted average price of $0.815 per share. The shares were sold automatically to cover tax withholding due upon the vesting of previously granted RSUs, and are described as a non-discretionary “sale to cover” transaction. After this sale, Swirsky directly holds 151,669 shares of MaxCyte common stock.
MaxCyte, Inc. received an updated ownership report from Cadian Capital affiliates and Eric Bannasch. As of December 31, 2025, they may have been deemed to beneficially own 3,683,052 shares of MaxCyte common stock, representing approximately 3.5% of the company’s outstanding shares.
The shares are directly held by Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP, which are advisory clients of Cadian Capital Management, LP. The reporting parties state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MaxCyte.
Capricorn Fund Managers Limited has filed a Schedule 13G reporting beneficial ownership of 8,200,000 shares of MaxCyte, Inc. common stock, representing 7.7% of the class as of the event date 01/30/2026.
Capricorn reports sole voting power over these 8,200,000 shares, with no shared voting power and no sole or shared dispositive power. The position is certified as being acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of MaxCyte. The filer is a United Kingdom entity acting as a foreign investment adviser under a regulatory regime it states is substantially comparable to that of a functionally equivalent U.S. institution.
BlackRock, Inc. has filed an amended Schedule 13G reporting beneficial ownership of 6,997,197 shares of MaxCyte, Inc. common stock, representing 6.6% of the class as of 12/31/2025.
BlackRock reports sole voting power over 6,901,491 shares and sole dispositive power over 6,997,197 shares, with no shared voting or dispositive power. The filing explains that the position reflects securities beneficially owned by certain BlackRock business units, and that various underlying persons have rights to dividends or sale proceeds, with no single person holding more than five percent of the outstanding common shares.
BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MaxCyte.
MaxCyte, Inc. reported that it has released preliminary unaudited financial results for the quarter and fiscal year ended December 31, 2025. The company furnished a press release dated January 12, 2026 as Exhibit 99.1 to a current report on Form 8-K under the item covering results of operations and financial condition. The information in this section and the exhibit is being furnished, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated by reference into other securities law filings.
MaxCyte, Inc. reported lower quarterly results as it navigates restructuring and integration of a recent acquisition. For the three months ended September 30, 2025, revenue was $6.8 million versus $8.2 million a year ago, driven by declines in instruments, consumables, and license activity. Net loss was $12.4 million compared to $11.6 million last year.
Nine-month revenue was $25.7 million versus $29.9 million in 2024, with operating cash use of $31.7 million. The company recorded $3.1 million in restructuring expense tied to a workforce reduction plan. Cash and cash equivalents were $13.0 million, with short‑term investments of $92.8 million and non‑current investments of $52.3 million as of September 30, 2025.
Customer concentration remained high: one customer represented 28% of Q3 revenue and 51% of accounts receivable. The SeQure Dx acquisition added capabilities in gene‑editing assessment; in Q3 it contributed $0.1 million of revenue and a $1.8 million net loss. Shares outstanding were 106.7 million as of November 7, 2025.
MaxCyte, Inc. furnished a current report announcing preliminary unaudited financial results for the quarter ended September 30, 2025 and reiterated its full‑year 2025 revenue guidance. The details are provided in a press release attached as Exhibit 99.1. The company stated that the information is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference except as expressly set forth by specific reference.
MaxCyte, Inc. disclosed anticipated costs tied to a workforce reduction plan. The company expects approximately $1.8 million for severance and healthcare continuation for directly employed personnel, $0.6 million for employees engaged through employer-of-record arrangements (covering severance, benefits, and statutory notice wages in jurisdictions such as Germany, France, and the United Kingdom), $0.4 million in wages and benefits required under Maryland's Mini-WARN Act (60 days' notice or pay in lieu), and $0.1 million in other costs including legal, consulting, and administrative expenses. In total, the disclosed near-term charge sums to $2.9 million, presented as estimates associated with implementing the Plan.